Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study
CONCLUSIONS: This analysis in a large patient cohort of the BCI Registry confirms and extends previous findings on the significant decision-making impact of BCI on EET. Incorporating BCI into clinical practice resulted in changes in physician recommendations, increased physician confidence, improved patient satisfaction, and reduced patient concerns regarding the cost, drug safety, and benefit of EET.PMID:38437792 | DOI:10.6004/jnccn.2023.7087 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - March 4, 2024 Category: Cancer & Oncology Authors: Tara B Sanft Jenna Wong Brandon O'Neal Natalia Siuliukina Rachel C Jankowitz Mark D Pegram Jenny R Fox Yi Zhang Kai Treuner Joyce A O'Shaughnessy Source Type: research
Case report: Cutaneous metastases as a first manifestation from breast cancer with concurrent gastric metastases
Conclusion: This case highlights the importance of considering atypical metastatic patterns in breast cancer and the potential efficacy of endocrine therapies in managing such cases. Moreover, it emphasizes the need for vigilance in breast cancer patients, especially those with ILC, as gastrointestinal symptoms may indicate gastric metastasis (GMs). Ultimately, early detection and appropriate treatment strategies, such as endocrine therapy, can contribute to improved outcomes in these challenging cases. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 4, 2024 Category: Drugs & Pharmacology Source Type: research
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al
Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01552-y. Online ahead of print.NO ABSTRACTPMID:38433180 | DOI:10.1007/s12282-024-01552-y (Source: Breast Cancer)
Source: Breast Cancer - March 3, 2024 Category: Cancer & Oncology Authors: Reiko Fukui Takahiro Watanabe Koji Morimoto Yukie Fujimoto Masayuki Nagahashi Eri Ishikawa Seiichi Hirota Yasuo Miyoshi Source Type: research
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al
Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01552-y. Online ahead of print.NO ABSTRACTPMID:38433180 | DOI:10.1007/s12282-024-01552-y (Source: Breast Cancer)
Source: Breast Cancer - March 3, 2024 Category: Cancer & Oncology Authors: Reiko Fukui Takahiro Watanabe Koji Morimoto Yukie Fujimoto Masayuki Nagahashi Eri Ishikawa Seiichi Hirota Yasuo Miyoshi Source Type: research
Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic
CONCLUSION: Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.PMID:38431780 | DOI:10.1093/oncolo/oyae031 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Zuzana Bielcikova Milos Holanek Iveta Selingerova Ondrej Sorejs Iveta Kolarova Renata Soumarova Jan Proks Lucie Reifova Vlastimila Cmejlova Lenka Linkova Michaela Zabojnikova Martina Chodacka Lucie Janovska Lenka Lisnerova Karolina Kasparova Denisa Pohank Source Type: research
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al
Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01552-y. Online ahead of print.NO ABSTRACTPMID:38433180 | DOI:10.1007/s12282-024-01552-y (Source: Breast Cancer)
Source: Breast Cancer - March 3, 2024 Category: Cancer & Oncology Authors: Reiko Fukui Takahiro Watanabe Koji Morimoto Yukie Fujimoto Masayuki Nagahashi Eri Ishikawa Seiichi Hirota Yasuo Miyoshi Source Type: research
A Multiparametric MRI-based Radiomics Model for Stratifying Postoperative Recurrence in Luminal B Breast Cancer
This study aims to develop an MRI-based radiomics model to assess the likelihood of recurrence in luminal B breast cancer. The study analyzed medical images and clinical data from 244 patients with luminal B breast cancer. Of 244 patients, 35 had experienced recurrence and 209 had not. The patients were randomly divided into the training set (51.5 ± 12.5 years old;n = 171) and the test set (51.7 ± 11.3 years old;n = 73) in a ratio of 7:3. The study employed univariate and multivariate Cox regression along with the least absolute shrinkage and selection operator (LASSO) regression methods to select rad...
Source: Journal of Digital Imaging - February 29, 2024 Category: Radiology Source Type: research
